Loading...
•
Mar 31, 2023
AbCellera Q1 2023 Earnings Report
AbCellera reported a decrease in revenue and a net loss for Q1 2023, while advancing partnered programs and molecules in the clinic.
Key Takeaways
AbCellera reported Q1 2023 financial results, with a total revenue of $12.2 million compared to $316.6 million in Q1 2022. The company generated a net loss of $40.1 million, or $(0.14) per share, compared to net earnings of $168.6 million, or $0.59 per share in Q1 2022. They reached a cumulative total of 177 programs under contract and maintained 101 partnered program starts. One additional molecule was advanced into the clinic, bringing the cumulative total to nine molecules.
Total revenue was $12.2 million, a decrease from $316.6 million in Q1 2022.
Net loss was $40.1 million, or $(0.14) per share, compared to net earnings of $168.6 million in Q1 2022.
Reached a cumulative total of 177 programs under contract with 41 different partners.
Advanced one additional molecule into the clinic, bringing the cumulative total to nine molecules.
Revenue by Segment
Forward Guidance
This press release contains forward-looking statements regarding AbCellera's ability to develop, commercialize and achieve market acceptance of its products and services, research and development efforts, business strategies, use of capital, results of operations and financial position, and plans and objectives for future operations.
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...